Sara Motka: We Create Greater Synergies Between Haemophilia and Haemoglobinopathies
Sara Motka, Head of Programmes at the Novo Nordisk Haemophilia and Haemoglobinopathies Foundation, reposted from Novo Nordisk Haemophilia and Haemoglobinopathies Foundation on LinkedIn:
”Thrilled to announce the expansion of NNHF! We will amplify our efforts in data-driven advocacy, forge stronger partnerships, and create greater synergies between haemophilia and haemoglobinopathies. Our mission goes beyond connecting and building opportunities for the global bleeding disorders community; we will aim to make a meaningful contribution to sickle cell disease and thalassaemia too. We will continue to connect, enable, and accelerate. Impacting care – Together!”
Qutoing Novo Nordisk Haemophilia and Haemoglobinopathies Foundation‘s post:
”We are now the Novo Nordisk Haemophilia and Haemoglobinopathies Foundation!
Proudly, we are unveiling our Foundation’s new chapter:
We are expanding our support beyond people with haemophilia to people with sickle cell disease and thalassaemia as well.
Building on two decades of work in haemophilia, and enabled by a renewed partnership with the Novo Nordisk Foundation and the continued funding from our founder Novo Nordisk, we are expanding our scope to include haemoglobinopathies. We will apply our proven, partnership-led model to develop tailored programmes that benefit people with haemophilia and haemoglobinopathies, their healthcare professionals, and families – always adapted to local needs.
Let us tell you more here.
Ludovic Helfgott, Mads Krogsgaard Thomsen, Maziar Mike Doustdar, Amy Shapiro, Stephanie Seremetis, Johnny Mahlangu, Ognenka Kozar, Denise B., Amos Gitonga M, Llyord Mwaniki, Célia Rohrer, Gatoto Carole, Sara Motka, Xio Fong Vilaysane, Elisa Eleftheriou, Natasha Honan.”

Stay updated with Hemostasis Today.
-
Mar 6, 2026, 16:51Priya Reehal: Highlighting The Central Role of Nurses in Cardio-Oncology
-
Mar 6, 2026, 16:50Rainer Kaiser: Blinatumomab Shows Remarkable Response in Multi-Refractory ITP and APS
-
Mar 6, 2026, 16:18Laila Shalabi: Clopidogrel, Aspirin, and the Role of PPIs in Coronary Artery Disease
-
Mar 6, 2026, 16:17Paul McKenzie: The Value of Gene Therapy in Bleeding Disorders
-
Mar 6, 2026, 16:15Basma El Homasany: The ‘Little Brain’ of the Heart and Its Role in Health
-
Mar 6, 2026, 16:14Jamal Rana: Family History and Polygenic Risk for Coronary Heart Disease
-
Mar 6, 2026, 15:43Kristy Ainslie: Breaking Down the Discovery and FDA Approval of Drug Carriers
-
Mar 6, 2026, 15:18Claudio Laudani: Efficacy and Safety of Colchicine for Secondary Prevention in Coronary Artery Disease
-
Mar 6, 2026, 15:09Chris Simon: Persona PLUS Receives FDA Clearance for Patent‑Protected Plasma Apheresis